drugset / Trial / NCT06264453

A Study to Evaluate the Efficacy and Safety of KH001 in Patients with Dentin Hypersensitivity

NCT06264453 ↗

Phase 2 Completed 171 enrolled HysensBio Co., Ltd
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to evaluate the efficacy and safety of KH001 in patients with dentin hypersensitivity.

Timeline

Start
2024-03-19
Primary completion
2024-09-25
Completion
2024-09-25

Drugs

EvaluationDrugModalityDoseRoute
Subject KH001 Unknown 0.2 mg/ml Topical
Subject KH001 Unknown 0.4 mg/ml Topical

Indications